Pseudoerythromycin A enol ether
Based on 1 Customer Validation
Pseudoerythromycin A enol ether (LY267108) is a degradation product of Erythromycin. Pseudoerythromycin A enol ether has no significant antimicrobial activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.48%
- CAS No.: 105882-69-7
- Formule: C37H65NO12
- Masse moléculaire:715.91
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-135233
N-Succinimidyl-S-acetylthioacetateProtein Modification Agent -
HY-122207
Erythromycin A enol etherErythromycin A Degradation Product -
HY-134095
Erythromycin A N-oxideErythromycin A Derivatives -
HY-122207R
Erythromycin A enol ether (Standard)Erythromycin A Degradation Product -
HY-W013266
N4-AcetylsulfamethoxazoleMetabolite -
HY-N7454
Anhydroerythromycin ABacterial Inhibitor -
HY-128459
N-Demethylerythromycin AErythromycin A Metabolite -
HY-W013266R
N4-Acetylsulfamethoxazole (Standard)Metabolite
Activité biologique
Description
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 105882-69-7
-
Appearance Solid
-
Masse moléculaire 715.91
-
Formule C37H65NO12
-
Color White to off-white
-
SMILES
C[C@@](OC([C@@H]([C@]1([H])[C@](C)(O)[C@H](O)CC)C)=C2C)(C2)[C@@H]([C@H]([C@@H]([C@H](C(O1)=O)C)O[C@H](O[C@H]3C)C[C@](C)([C@H]3O)OC)C)O[C@H](O[C@@H]4C)[C@@H]([C@H](C4)N(C)C)O
-
Synonyms
LY267108
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Pendela M, et al. Combined use of liquid chromatography with mass spectrometry and nuclear magnetic resonance for the identification of degradation compounds in an erythromycin formulation. Anal Bioanal Chem. 2012;402(2):781-790. [Content Brief]
[2]. Greenwood B, et al. Effects of LY267108, an erythromycin analogue derivative, on lower esophageal sphincter function in the cat. Gastroenterology. 1994;106(3):624-628. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pseudoerythromycin A enol ether Related Classifications
HY-112057 Related Classifications
Powered by Bioz